NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model

Acta Pharmacologica Sinica

Volumn 30, Issue 7, 2009, Pages 980-986

  Xu, Peng ^a,c   Qu, Jie Ming ^a   Xu, Jin Fu ^b   Zhang, Jing ^a   Jiang, Hong Ni ^a   Zhang, Hui Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Amphotericin B; Invasive pulmonary aspergillosis; N acetyl l cysteine; Neutropenia; Oxidant antioxidant therapy

Indexed keywords

ACETYLCYSTEINE; AMPHOTERICIN B; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; MALONALDEHYDE; PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MECHANISM; FUNGAL DETECTION; LUNG ASPERGILLOSIS; LUNG INJURY; MALE; MOUSE; NEUTROPENIA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; TISSUE LEVEL;

ACETYLCYSTEINE; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-10; INVASIVE PULMONARY ASPERGILLOSIS; LUNG INJURY; MALE; MICE; MICE, INBRED BALB C; NEUTROPENIA; OXIDATIVE STRESS; RANDOM ALLOCATION; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651159030     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.83     Document Type: Article

References (41)

1. Reichenberger F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002; 19: 743-55.
2. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans W, Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-5.
3. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Ortiz-Leyba C, León C, Álvarez-Lerma F. Isolation of Aspergillus spp from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191-199
4. Vandewoude K, Blot S, Depuydt P, Benoit D, Temmerman W, Colardyn F. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10: R31.
5. Madan T, Kaur S, Saxena S, Singh M, Kishore U, Thiel S. Role of collectins in innate immunity against Aspergillosis. Med Mycol 2005, 43 Suppl 1: 155-63.
6. Becker MJ, de Marie S, Fens MH, Verbrugh HA, Bakker-Woudenberg IA. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary Aspergillosis. J Antimicrob Chemother 2003; 52: 428-34.
7. Brakhage AA. Systemic fungal infections caused by Aspergillus species: epidemiology, infection process and virulence determinants. Curr Drug Targets 2005; 6: 875-86.
8. Saxena S, Bhatnagar PK, Ghosh PC, Usha Sarma P. Effect of amphotericin B lipid formulation on immune response in Aspergillosis. Int J Pharm 1999; 188: 19-30.
9. Vandewoude KH, Vogelaers, D, Blot SI. Aspergillosis in the ICU - the new 21st century problem? Med Mycol 2006; 44 Suppl: 71-6.
10. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive Aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-17.
11. Morcillo EJ, Estrela J, Cortijo J. Oxidative stress and pulmonary inflammation: pharmacological intervention with antioxidants. Pharmacol Res 1999, 40: 393-402.
12. Bellocchio S, Moretti S, Perruccio K, Fallarino F, Bozza S, Montagnoli C, et al. TLRs govern neutrophil activity in Aspergillosis. J Immunol 2004; 173: 7406-15.
13. Chauhan N, Latgé JP, Calderone R. Signalling and oxidant adaptation in Candida albicans and Aspergillus fumigatus. Nat Rev Microbiol 2006; 4: 435-44.
14. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629-36.
15. Huang XL, Ling YL. The antioxidant therapy of N-acetylcysteine to pulmonary injury. Int J Respir 2001; 21: 64-9
16. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-27.
17. Sbaraglia G, D'Errico P, Serafni S, Vecchiarelli L, Perito S. Pathogenicity of various species of Candida in mice immunodepressed with cyclophosphamide. Boll Soc Ital Biol Sper 1984; 60: 1421-6.
18. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericinB (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxy cholate (Fungizone) in a rat model of pulmonary Aspergillosis. J Antimicrob Chemother 1996; 38: 215- 25.
19. Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, et al. A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice. Chia J Dis Control Prev 2006; 10: 593-6.
20. Liu KX, Wu WK, He W, Liu CL. Ginkgo biloba extract (Egb 761) attenuates lung injury induced by intestinal ischemia/reperfusion in rats: roles of oxidative stress and nitric oxide. World J Gastroenterol 2007; 13: 299-305.
21. Grocott RG. A stain for fungi in tissue section and smears using Gomori's methenamine-silver nitrate technic. Am J Clin Pathol 1955; 25: 975-9.
22. Murao Y, Loomis W, Wolf P, Hoyt DB, Junger WG. Effect of dose of hypertonic saline on its potential to prevent lung tissue damage in a mouse model of hemorrhagic shock. Shock 2003; 20: 29-34.
23. Kotanidou A, Loutrari H, Papadomichelakis E, Glynos C, Magkou C, Armaganidis A, et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 2006; 45: 134-40.
24. Nemzek JA, Bolgos GL, Williams BA, Remick DG. Differences in normal values for murine white blood cell counts and other hemato-logical parameters based on sampling site. Infamm Res 2001; 50: 523-7
25. Chiller TM, Sobel RA, Capilla Luque J, Clemons KV, Stevens DA. Effcacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813-5.
26. Clemons KV, Stevens DA. Comparative effcacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob Agents Chemother 2004; 48: 1047-50.
27. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52: 656-62.
28. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dosedependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary Aspergillosis. J Antimicrob Chemother 2008; 61: 1140-4.
29. Latgé JP. The pathobiology of Aspergillus fumigatus. Trends Microbiol 2001; 9: 382-9.
30. Pasqualotto A. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2008; S1-S10.
31. Balloy V, Huerre M, Latgé JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494-503
32. Luther K, Rohde M, Sturm K, Kotz A, Heesemann J, Ebel F. Characterisation of the phagocytic uptake of Aspergillus fumigatus conidia by macrophages. Microbes Infect 2008; 10: 175-84.
33. Latgé JP. Aspergillus fumigatus and Aspergillosis. Clin Microbiol Rev 1999; 12: 310-50.
34. Reeves EP, Nagl M, Godovac-Zimmermann J, Segal AW. Reassessment of the microbicidal activity of reactive oxygen species and hypochlorous acid with reference to the phagocytic vacuole of the neutrophil granulocyte. J Med Microbiol 2003; 52: 643-51.
35. Bellocchio S, Moretti S, Perruccio K, Fallarino F, Bozza S, Montagnol C, et al. TLRs govern neutrophil activity in Aspergillosis. J Immunol 2004; 173: 7406-15
36. Hohl TM, Marta Feldmesser EC. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot Cell 2007; 6: 1953-63.
37. Xu JF, Qu JM. The effect of antioxidant treatment in pneumonia of granulocytopenic rats. Chin J Internal Med 2004; 43: 852-6
38. Sainz J, Hassan L, Perez E, Romero A, Moratalla A, López- Fernández E, et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary Aspergillosis. Immunol Lett 2007; 109: 76-82.
39. Stevens DA. Th1/Th2 in aspergillosis. Med Mycol 2006; 44 Suppl: 229-35.
40. Aihara M, Dobashi K, Akiyama M, Naruse I, Nakazawa T, Mori M. Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages. Respiration 2000; 67: 662-71.
41. Sambatakou H, Pravica V, Hutchinson IV, Denning DW. Cytokine profiling of pulmonary Aspergillosis. Int J Immunogenet 2006; 33: 297-302.